The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index; 4 of the 14 sources its claims cite were checked for support.
Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with poor prognosis and limited therapeutic options. The incidence of IPF increases with age, and ageing-related mechanisms such as cellular senescence have been proposed as pathogenic drivers. The lung alveolar epithelium represents a major site of tissue injury in IPF and senescence of this cell population is probably detrimental to lung repair. However, the potential pathomechanisms of alveolar epithelial cell senescence and the impact of senolytic drugs on senescent lung cells and fibrosis remain unknown. Here we demonstrate that lung epithelial cells exhibit increased P16 and P21 expression as well as senescence-associated β-galactosidase activity in experimental and human lung fibrosis tissue and primary cells. Primary fibrotic mouse alveolar epithelial type (AT)II cells secreted increased amounts of senescence-associated secretory phenotype (SASP) factors in vitro , as analysed using quantitative PCR, mass spectrometry and ELISA. Importantly, pharmacological clearance of senescent cells by induction of apoptosis in fibrotic ATII cells or ex vivo three-dimensional lung tissue cultures reduced SASP factors and extracellular matrix markers, while increasing alveolar epithelial markers . These data indicate that alveolar epithelial cell senescence contributes to lung fibrosis development and that senolytic drugs may be a viable therapeutic option for IPF.
Overview
CoChat Summary
TL;DR
In human IPF and bleomycin-induced murine lung fibrosis, alveolar epithelial cells show increased senescence markers and a profibrotic SASP. Senolytic dasatinib+quercetin treatment depleted senescent ATII cells and ex vivo 3D lung tissue cultures, reduced SASP/extracellular matrix markers, and increased alveolar epithelial markers.
Key findings
- IPF lung homogenates had increased P16 mRNA (mean±sd ΔCt donor −1.91±0.74 versus IPF 0.74±0.40, p<0.01), while P21 mRNA was unchanged; P16 and P21 protein were increased by Western blot, and P16/P21 localized largely to proSP-C+ KRT7+ ATII cells in IPF lungs.
- In bleomycin-treated mice, P16 and P21 were upregulated (day 14 P16: PBS −5.66±0.34 versus Bleo −4.33±0.21; P21: PBS −0.64±0.22 versus Bleo 1.42±0.22; p<0.001); SA-β-galactosidase activity increased in fibrotic 3D-LTCs, and senescence-associated gene enrichment was found in fibrotic pmATII cells but not whole lung or pmFb.
- Freshly isolated fibrotic EpCAM+ pmATII cells had increased SA-β-galactosidase; after 48 h culture this remained 2.45±0.45-fold over healthy cells, with increased P16/P21, H3K9me3 foci, and Spp1/Mmp2; secretome analysis found 52% of detected SASP components upregulated >1.5-fold and 10% downregulated.
- Dasatinib+quercetin reduced senescent cells, P16, SASP factors (Mmp12, Serpine1, Spp1), ECM components (Collagen1a1, Collagen5a3, Fibronectin), IL-6 (DMSO 3.95±0.81-fold over control versus DQ 1.34±0.65-fold), and Wisp1 (DMSO 2.10±0.91 versus DQ 0.71±0.26), while increasing E-cadherin, Sftpc, Sftpa, and SP-C in ATII cells and 3D-LTCs.
Methods
- Human explanted IPF and donor lung tissue plus primary human ATII cells; mouse bleomycin-induced lung fibrosis (2 U·kg−1 body weight, sacrificed at day 7, 14, or 21) versus PBS controls; primary mouse ATII cells and three-dimensional lung tissue cultures (3D-LTCs).
- Senescence assessed by qPCR for P16/P21, Western blotting, immunohistochemistry, SA-β-galactosidase staining/flow cytometry, H3K9me3 foci, and gene set enrichment analysis; SASP assessed by quantitative PCR, mass spectrometry, and ELISA.
- Senolytic treatment used dasatinib and quercetin; apoptosis assessed by cleaved caspase 3 and annexin V; statistics used t-tests, paired t-tests, one-way ANOVA with Newman–Keuls multiple comparison, and Pearson correlation, with p<0.05 considered significant.
Limitations
- Stated: lack of reliable and specific mouse P16 antibodies prevented analysis of P16 at the protein level; future in vivo studies targeting specific senescent cell populations are needed; human lung tissue confirmation is needed; other cell types, such as fibroblasts, are likely also affected by senolytic treatment in 3D-LTCs.
- Stated/evident: the therapeutic evidence is largely in vitro and ex vivo, so in vivo efficacy and the causal contribution of alveolar epithelial senescence to human IPF remain to be established.
- Evident: senolytic effects are not cell-type-specific in the ex vivo system, and the text does not report human cohort sample sizes or detailed clinical characteristics.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![FIGURE 2 Senescence markers are upregulated in experimental lung fibrosis. Mice were instilled with PBS or bleomycin (Bleo) and sacrificed at the timepoints indicated. a) Gene expression of P16 and P21 in lung homogenates of mice sacrificed at day 7, 14 or 21 was measured using quantitative PCR and normalised to Hprt. Change in cycle threshold (ΔCt) is presented as mean±sem; n=3 for PBS and n=5 for Bleo. Statistical significance was tested using one-way ANOVA followed by Newman–Keuls' multiple comparison test. b) Immunoblot of P21 protein in mouse whole-lung homogenates of mice treated with PBS or Bleo and sacrificed after 7 or 14 days. β-Actin was used as a loading control. Respective sizes of marker are indicated. Data were quantified and normalised to loading control. Data are presented as mean±sem; n=9. Statistical significance was tested using one-way ANOVA followed by Newman-Keuls' multiple comparison test. c, d) Three-dimensional lung tissue cultures (3D-LTCs) were obtained from mice instilled with PBS or Bleo and sacrificed at day 14. 3D-LTCs were stained for senescence-associated β-galactosidase activity and c) macroscopic images and d) microscopic (magnification of 200× or 400×) images were taken. Epithelial cells are marked by arrows. e) Enrichment of senescence-associated genes [31] in microarray data of i) whole lung [32] (GSE16846), ii) mouse fibroblasts [33] (GSE42564) or iii) primary mouse (pm) alveolar epithelial type (AT)II cells [26] of mice with experimental lung fibrosis induced by Bleo. FDR: false discovery rate; FWER: family-wise error rate. *: p<0.05; ***: p<0.001.](https://figures.cochat.ai/paper-figures/56638935b27e4e57934b4d3b372306d6/senolytic-drugs-target-alveolar-epithelial-cell-function-and-attenuate-figure-2.jpg)
![FIGURE 3 Senescence markers are upregulated in alveolar epithelial type (AT)II cells in experimental lung fibrosis. Mice were instilled with either PBS or bleomycin (Bleo). At day 14 after instillation, mice were sacrificed and primary mouse (pm)ATII cells were isolated. a) Immunofluorescence staining of fibrotic or nonfibrotic pmATII cells on cover slips for epithelial cell marker expression at day 2 after isolation. Fluorescent images represent a 400× magnification. b) pmATII cells were analysed for epithelial cell adhesion molecule (EpCAM) positivity and senescence-associated (SA)-β-galactosidase activity by fluorescence-activated cell sorting (FACS) directly after isolation. Representative dot blots of the EpCAM+ population are shown for PBS and Bleo, as well as quantifications of percentages of senescent cells of the EpCAM+ population. Means were compared to time-matched PBS controls using unpaired t-tests; n=3. c) pmATII cells (day 2) were analysed for SA-β-galactosidase activity using FACS. Representative dot blots are shown for PBS and Bleo pmATII cells incubated with C12FDG or respective controls, a representative histogram comparing PBS and Bleo pmATII cells incubated with C12FDG as well as quantifications of percentages of senescent cells normalised to respective PBS control. Means were compared to time-matched PBS controls using unpaired t-tests; n=3. d) pmATII cells (day 2) were stained for SA-β-galactosidase activity and blue cells and total cells were counted. Representative images and quantitative data normalised to respective PBS controls are shown. Data represent mean±sem. Means were compared to time-matched PBS controls using unpaired t-tests; n=3. e) Gene expression of senescence-associated genes in freshly isolated pmATII cells from PBS- or Bleo-treated mice was measured using quantitative PCR. Data were normalised to Hprt. Change in threshold cycle (ΔCt) is presented as mean±sem; n=3–4 for PBS and n=8 for Bleo. Means were compared to time-matched PBS controls using unpaired t-tests. f–h) pmATII cells isolated from PBS- or Bleo-treated mice were plated onto plastic tissue culture plates. After 48 h of culture, the supernatant was collected and analysed using mass spectrometry proteomics. The senescence-associated secretory phenotype (SASP) list [9] was compared to the list of secreted proteins (1.5-fold upregulated or downregulated). f) A Venn diagram (BioVenn; [38]) showing the overlap of SASP proteins with the up-/downregulated proteins in the pmATII supernatant. g) Percentage of detected SASP factors that are upregulated (>1.5-fold) or downregulated (<-1.5-fold) or not changed. h) List of upregulated SASP components >1.5-fold Bleo/PBS. CK: cytokeratin; ZO: zona occludens; SMA: smooth muscle actin. *: p<0.05; ***: p<0.001.](https://figures.cochat.ai/paper-figures/6ca25af067a345fc9715e0545f80b71a/senolytic-drugs-target-alveolar-epithelial-cell-function-and-attenuate-figure-3.jpg)




Verification
Claims the paper makes
2 Valid · 0 Not valid · 3 Not checked · 60 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“cellular senescence has been linked to the pathogenesis of chronic lung diseases such as chronic obstructive pulmonary disease [14, 15] or IPF [16–20].”
§ Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo > Introduction
What the sources say
- Not checked yetcites [14] source
- Not checked yetcites [15] source
- Supportedcites [16] Disayabutr, 2016, miR-34 miRNAs regulate cellular senescence in type II alveolar epithelial cells of patients with idiopathic pulmonary fibrosis, PLoS One source
This source is cited for the IPF portion of the sentence, not COPD. The Introduction associates cellular senescence with IPF, and the Discussion calls it a pathologic feature of IPF and reports elevated senescence markers in IPF lung cells. Page numbers are not available in the supplied copy. (LLM, conf=0.94)
- Supportedcites [17] Hecker, 2014, Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance, Sci Transl Med source
This source supports the IPF portion of the sentence, to which the [16–20] citations are attached. The Results section reports a senescent cellular phenotype in fibroblastic foci of human IPF lungs, and the Discussion explicitly describes a link between cellular senescence and IPF. The COPD portion is cited separately. (LLM, conf=0.92)
- Not checked yetcites [18] source
- Not checked yetcites [19] source
- Not checked yetcites [20] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to lung fibroblasts, evidence has emerged that alveolar epithelial cells can become senescent in IPF [16, 20, 24].”
§ Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo > Introduction
What the sources say
- Supportedcites [16] Disayabutr, 2016, miR-34 miRNAs regulate cellular senescence in type II alveolar epithelial cells of patients with idiopathic pulmonary fibrosis, PLoS One source
The Results section (‘Expression of senescence markers in isolated type II AECs’) reports senescence markers and SA-βgal activity in type II alveolar epithelial cells from IPF lungs. The Discussion likewise concludes that these cells are a major source of senescent cells in IPF lung. (LLM, conf=0.94)
- Not checked yetcites [20] source
- Supportedcites [24] Naikawadi, 2016, Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis, JCI Insight source
The Introduction reports that type II alveolar epithelial cells in IPF lungs express senescence markers. The Discussion likewise identifies expression of molecular markers of senescence as a defect in IPF type II alveolar epithelial cells. These passages support the cited claim. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Primary fibrotic mouse alveolar epithelial type (AT)II cells secreted increased amounts of senescence-associated secretory phenotype (SASP) factors in vitro, as analysed using quantitative PCR, mass spectrometry and ELISA.”
§ Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while no or only sporadic staining for P16 and P21 was observed in donor lungs (figure 1d; arrows).”
§ Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo > Results > Senescence marker expression is upregulated in the lung epithelium in IPF
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 48 h of culture, fibrotic ATII cells maintained an increase of 2.45±0.45-fold in SA-β-galactosidase staining over healthy cells (figure 3c).”
§ Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo > Results > Increased senescence of ATII cells in experimental lung fibrosis
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims
Create a free account to see all 65 claims and to verify the 10 references still open.
- It may state two separate claims as one. 23
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A major challenge in the field has been to reliably identify senescent cells in tissues and organs.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Preclinical evidence suggests that senescent fibroblasts and alveolar epithelial cells contribute to pulmonary fibrosis and supports cellular senescence as a potential target for treatment for bleomycin-induced lung injury model of pulmonary fibrosis that may be translationally relevant to humans.5,10,11”
From Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability (2023) · cites this paper as [11]
Experimental — accuracy not yet measured
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
Cited by
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Strunz, M., Simon, L. M., Ansari, M., Kathiriya, J. J., Angelidis, I., Mayr, C. H., Tsidiridis, G., Lange, M., Mattner, L. F., Yee, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17358-3 · Cited by 728
Self-citationShared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationEvasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
Metadata
- Authors
- Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., Wagner, D. E., Günther, A., & Königshoff, M.
- Affiliations
- Helmholtz Munich (DE)
- Justus-Liebig-Universität Gießen (DE)
- Asklepios Fachkliniken München-Gauting (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1602367
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC5593348
- OpenAlex
- W2744177930
- Cited by
- 403
- References
- 64
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 34 · 2023: 40 · 2022: 33 · 2021: 81 · 2020: 57 · 2019: 45 · 2018: 43 · 2017: 5
- FWCI
- 33.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
- Lund University Publications (Lund University) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Whitaker International Scholar Fellowship
- Helmholtz Munich Postdoctoral Program
- Helmholtz Association
- German Center of Lung Research
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- senolytics, idiopathic pulmonary fibrosis, cellular senescence, alveolar epithelial cells, alveolar type II cells, senescence-associated secretory phenotype, senolytic therapy, extracellular matrix, pulmonary fibrosis, apoptosis, p16, p21, senescence-associated β-galactosidase
- MeSH terms
- Animals, Humans, Lung, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase Inhibitor p21, Mice, Idiopathic Pulmonary Fibrosis, Alveolar Epithelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. https://app.cochat.ai/papers/10.1183/13993003.02367-2016
- The paper
- Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., Wagner, D. E., Günther, A., & Königshoff, M. (2017). Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. European Respiratory Journal. https://doi.org/10.1183/13993003.02367-2016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.